NO962752L - Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose - Google Patents

Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose

Info

Publication number
NO962752L
NO962752L NO962752A NO962752A NO962752L NO 962752 L NO962752 L NO 962752L NO 962752 A NO962752 A NO 962752A NO 962752 A NO962752 A NO 962752A NO 962752 L NO962752 L NO 962752L
Authority
NO
Norway
Prior art keywords
bone loss
diaryl
osteoporosis
treatment
medicament
Prior art date
Application number
NO962752A
Other languages
English (en)
Norwegian (no)
Other versions
NO962752D0 (no
Inventor
Virender M Labroo
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of NO962752D0 publication Critical patent/NO962752D0/no
Publication of NO962752L publication Critical patent/NO962752L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO962752A 1993-12-30 1996-06-28 Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose NO962752L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/175,899 US5389646A (en) 1993-12-30 1993-12-30 Methods for treatment and prevention of bone loss using 2,3-benzopyrans
PCT/US1994/014568 WO1995017892A1 (fr) 1993-12-30 1994-12-14 Utilisation des derives 2,3-diaryl-1-benzopyrane dans la production d'un medicament employe dans le traitement et la prevention de la diminution du volume du tissu osseux et de l'osteoporose

Publications (2)

Publication Number Publication Date
NO962752D0 NO962752D0 (no) 1996-06-28
NO962752L true NO962752L (no) 1996-08-29

Family

ID=22642125

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962752A NO962752L (no) 1993-12-30 1996-06-28 Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose

Country Status (11)

Country Link
US (1) US5389646A (fr)
KR (1) KR100213963B1 (fr)
CN (1) CN1142767A (fr)
AU (1) AU701411B2 (fr)
CA (1) CA2180178C (fr)
CZ (1) CZ192396A3 (fr)
FI (1) FI962685A7 (fr)
HU (1) HUT75705A (fr)
NO (1) NO962752L (fr)
RU (1) RU2166316C2 (fr)
WO (1) WO1995017892A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5637598A (en) * 1994-11-18 1997-06-10 Eli Lilly And Company Methods of inhibiting bone loss
WO1997048694A1 (fr) * 1996-06-20 1997-12-24 Board Of Regents, The University Of Texas System Composes et procedes d'obtention de preparations pharmacologiquement actives et leurs utilisations
US6043269A (en) * 1996-10-28 2000-03-28 Novo Nordisk A/S cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6876427B2 (en) 2001-09-21 2005-04-05 3M Innovative Properties Company Cholesteric liquid crystal optical bodies and methods of manufacture and use
CA2581316C (fr) * 2004-09-21 2013-09-10 Novogen Research Pty Ltd Derives de chromane substitues, medicaments et utilisation a des fins therapeutiques
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
EP2635273B1 (fr) 2010-11-01 2020-01-08 MEI Pharma, Inc. Compositions d'isoflavonoïdes et méthodes de traitement du cancer
WO2013090829A1 (fr) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Modulateurs des récepteurs des œstrogènes et ses utilisations
CN116139125A (zh) 2015-02-02 2023-05-23 梅制药公司 联合治疗
CN104926776B (zh) * 2015-07-06 2018-05-25 江南大学 4-苯甲酰亚甲基黄烷类衍生物的绿色合成方法
WO2017072792A1 (fr) 2015-10-27 2017-05-04 Sun Pharma Advanced Research Company Limited Nouveaux antioestrogènes hétérocycliques
KR20220046586A (ko) 2019-07-22 2022-04-14 썬 파마 어드밴스트 리서치 컴패니 리미티드 선택적 에스트로겐 수용체 분해제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1518002C3 (de) * 1965-01-02 1975-01-23 Merck Patent Gmbh, 6100 Darmstadt Isoflavane und Isoflavene und Verfahren zu Ihrer Herstellung sowie diese enthaltende Arzneimittel
US4210644A (en) * 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US4489056A (en) * 1982-06-30 1984-12-18 Merck & Co., Inc. Acid anhydrides as rate controlling agent for the erosion of polymers which latter polymers have beneficial substances dispersed throughout their matrix or where the polymer matrix surrounds the beneficial substance
US4644012A (en) * 1983-12-21 1987-02-17 Takeda Chemical Industries, Ltd. Treatment for osteoporosis
JPS60132976A (ja) * 1983-12-21 1985-07-16 Takeda Chem Ind Ltd 新規３−フエニル−４ｈ−１−ベンゾピラン−４−オン誘導体
US5254568A (en) * 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
JP3502403B2 (ja) * 1991-12-16 2004-03-02 アベンティス ファーマ株式会社 骨吸収抑制剤
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives

Also Published As

Publication number Publication date
US5389646A (en) 1995-02-14
AU701411B2 (en) 1999-01-28
WO1995017892A1 (fr) 1995-07-06
HU9601786D0 (en) 1996-09-30
FI962685A0 (fi) 1996-06-28
FI962685L (fi) 1996-08-28
CZ192396A3 (en) 1997-03-12
CA2180178C (fr) 2001-03-20
AU1403995A (en) 1995-07-17
CA2180178A1 (fr) 1995-07-06
RU2166316C2 (ru) 2001-05-10
HUT75705A (en) 1997-05-28
NO962752D0 (no) 1996-06-28
FI962685A7 (fi) 1996-08-28
KR100213963B1 (en) 1999-08-02
CN1142767A (zh) 1997-02-12

Similar Documents

Publication Publication Date Title
DK0688214T3 (da) Fremgangsmåder til inhibering af knogletab med 3,4-diarylchroman
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
ATE215816T1 (de) Feste oral anzuwendende arzeneiform
DK0759757T3 (da) Orale, væskeformige alendronatformuleringer
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
DK1623703T3 (da) Hydrocodonformuleringer med kontrolleret frigivelse
AP9400645A0 (en) Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release sold dosage forms of medicaments prepared thereby.
BG104620A (en) Oral pharmaceutical extended release dosage form
DK0833643T3 (da) Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
NO306894B1 (no) Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
DK0688215T3 (da) 3,4-diarylchromaner til behandling af dermatitis
NO912416D0 (no) Terapeutisk aktiv benzimidazolforbindelse og fremgangsmaate for dens fremstilling.
AU1277792A (en) Compositions for topical administration containing fluticasone propionate and oxiconazole or its salts
EP0302714A3 (fr) Composition pharmaceutique pour le traitement des maladies affaiblissant les os
NO178336C (no) Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse og mellomprodukter
WO2003099214A3 (fr) Formulations de biguanide
MY114610A (en) Controlled drug delivery system for diltiazem.
MY110769A (en) Controlled release oxycodone compositions.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application